

# Murtadha Al-Khabori

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3802435/publications.pdf>

Version: 2024-02-01

281  
papers

5,143  
citations

109264

35  
h-index

128225

60  
g-index

288  
all docs

288  
docs citations

288  
times ranked

6313  
citing authors

#	ARTICLE	IF	CITATIONS
1	One million haemopoietic stem-cell transplants: a retrospective observational study. <i>Lancet Haematology</i> , 2015, 2, e91-e100.	2.2	329
2	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology</i> , 2020, 7, e157-e167.	2.2	319
3	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	0.6	278
4	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	6.9	189
5	Similar outcome of upfront unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the <scp>UK</scp> Paediatric <scp>BMT</scp> Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of <scp>EBMT</scp>. <i>British Journal of Haematology</i> , 2015, 171, 585-594.	1.2	146
6	Combined Corticosteroid and Antiviral Treatment for Bell Palsy. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 985.	3.8	140
7	Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. <i>Haematologica</i> , 2013, 98, 1282-1290.	1.7	110
8	Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. <i>British Journal of Haematology</i> , 2015, 169, 565-573.	1.2	104
9	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. <i>Haematologica</i> , 2022, 107, 1045-1053.	1.7	87
10	Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 237-245.	1.7	82
11	Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 896-899.	2.0	78
12	Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. <i>Bone Marrow Transplantation</i> , 2020, 55, 1093-1102.	1.3	78
13	Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. <i>Blood</i> , 2017, 129, 1636-1645.	0.6	77
14	Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. <i>Blood Advances</i> , 2017, 1, 477-485.	2.5	76
15	Proteomics: Concepts and applications in human medicine. <i>World Journal of Biological Chemistry</i> , 2021, 12, 57-69.	1.7	75
16	Autologous Stem Cell Transplantation in Follicular Lymphoma: a Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2012, 104, 18-28.	3.0	74
17	Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2014, 99, 1574-1581.	1.7	73
18	Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation and Association With Occurrence and Outcome of Invasive Aspergillosis. <i>Journal of Infectious Diseases</i> , 2015, 212, 959-967.	1.9	63

#	ARTICLE	IF	CITATIONS
19	Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. <i>Bone Marrow Transplantation</i> , 2019, 54, 44-52.	1.3	59
20	Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1841-1846.	2.0	53
21	Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2134-2142.	2.0	52
22	Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 108.	6.9	51
23	Impact of the revised international Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , 2015, 100, 400-408.	1.7	50
24	Pathogenesis of Acquired Aplastic Anemia and the Role of the Bone Marrow Microenvironment. <i>Frontiers in Oncology</i> , 2018, 8, 587.	1.3	49
25	High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2019, 54, 540-548.	1.3	49
26	Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 522-528.	2.0	48
27	Multispecific Aspergillus T Cells Selected by CD137 or CD154 Induce Protective Immune Responses Against the Most Relevant Mold Infections. <i>Journal of Infectious Diseases</i> , 2015, 211, 1251-1261.	1.9	47
28	Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. <i>Lancet Haematology</i> , 2015, 2, e384-e392.	2.2	46
29	Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party. <i>Haematologica</i> , 2019, 104, e398-e401.	1.7	46
30	Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?. <i>Blood</i> , 2018, 131, 1989-1992.	0.6	43
31	Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 26.	2.8	40
32	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2021, 96, 69-79.	2.0	40
33	Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. <i>Leukemia</i> , 2021, 35, 3551-3560.	3.3	40
34	Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison. <i>Nutrition</i> , 2017, 35, 43-50.	1.1	39
35	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (IACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 681-694.	1.3	39
36	Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia. <i>Oman Medical Journal</i> , 2013, 28, 121-124.	0.3	38

#	ARTICLE	IF	CITATIONS
37	Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. <i>EBioMedicine</i> , 2015, 2, 2101-2109.	2.7	36
38	Circulating activated neutrophils in COVID-19: An independent predictor for mechanical ventilation and death. <i>International Journal of Infectious Diseases</i> , 2021, 106, 155-159.	1.5	36
39	Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study. <i>Transplant Infectious Disease</i> , 2018, 20, e12981.	0.7	35
40	The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT. <i>Annals of Hematology</i> , 2019, 98, 1755-1763.	0.8	35
41	Role of tumour angiogenesis in haematological malignancies. <i>Swiss Medical Weekly</i> , 2014, 144, w14050.	0.8	35
42	Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2017, 92, 997-1003.	2.0	34
43	Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1223-1231.	1.7	34
44	Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2021, 35, 215-224.	3.3	34
45	Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 1906-1917.	1.3	33
46	Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. <i>Blood Advances</i> , 2021, 5, 1110-1121.	2.5	33
47	Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends. <i>Bone Marrow Transplantation</i> , 2019, 54, 402-417.	1.3	31
48	Novel therapeutic options in Acute Myeloid Leukemia. <i>Leukemia Research Reports</i> , 2016, 6, 39-49.	0.2	30
49	Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. <i>Cancer</i> , 2018, 124, 2134-2141.	2.0	30
50	Use of eltrombopag in aplastic anemia in Europe. <i>Annals of Hematology</i> , 2019, 98, 1341-1350.	0.8	30
51	Immunoglobulin G4-Related Disease: An Update. <i>Oman Medical Journal</i> , 2018, 33, 97-103.	0.3	29
52	Angiogenesis in myeloproliferative neoplasms, new markers and future directions. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 206-210.	0.3	26
53	Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with <sc>CLL</sc>: a retrospective analysis from the European Society for Blood and Marrow Transplantation (<sc>EBMT</sc>). <i>British Journal of Haematology</i> , 2017, 178, 521-533.	1.2	26
54	Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. <i>Journal of Human Genetics</i> , 2012, 57, 665-669.	1.1	25

#	ARTICLE	IF	CITATIONS
55	Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1513.	3.8	24
56	Extreme Preterm Premature Rupture of Membranes: Risk Factors and Feto Maternal Outcomes. <i>Oman Medical Journal</i> , 2013, 28, 108-111.	0.3	22
57	Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. <i>Cancer Genomics and Proteomics</i> , 2016, 13, 317-29.	1.0	22
58	Validation of a non-invasive pulse CO-oximetry based hemoglobin estimation in normal blood donors. <i>Transfusion and Apheresis Science</i> , 2014, 50, 95-98.	0.5	21
59	Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2021, 223, 1564-1575.	1.9	21
60	Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 61-65.	0.6	20
61	Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML). <i>Leukemia and Lymphoma</i> , 2017, 58, 1068-1075.	0.6	20
62	Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1211-1219.	2.0	20
63	Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2008-2016.	2.0	20
64	Current evidence and the emerging role of eltrombopag in severe aplastic anemia. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072199812.	1.1	20
65	Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e334-e343.	2.2	20
66	Hypothyroidism following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. <i>Leukemia Research</i> , 2017, 58, 43-47.	0.4	19
67	Therapeutic drug monitoring-guided dosing of busulfan differs from weight-based dosing in hematopoietic stem cell transplant patients. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 70-78.	0.6	19
68	Diagnosis of invasive mold diseases in patients with hematological malignancies using <i>Aspergillus</i> , <i>Mucorales</i> and panfungal PCR in BAL. <i>Transplant Infectious Disease</i> , 2018, 20, e12953.	0.7	19
69	Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days. <i>Transfusion</i> , 2019, 59, 3350-3361.	0.8	19
70	The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2372-2377.	2.0	19
71	Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT. <i>Cancer</i> , 2018, 124, 2523-2533.	2.0	18
72	Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 256-265.	1.7	18

#	ARTICLE	IF	CITATIONS
73	Lung Resection in Hematologic Patients With Pulmonary Invasive Fungal Disease. <i>Chest</i> , 2012, 142, 988-995.	0.4	17
74	Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. <i>Journal of Hematology and Oncology</i> , 2018, 11, 127.	6.9	17
75	Cyclosporine levels $\geq 195 \mu\text{g/L}$ on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2019, 98, 971-977.	0.8	17
76	Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. <i>Blood Advances</i> , 2020, 4, 3699-3707.	2.5	17
77	Noninvasive assessment and risk factors of liver fibrosis in patients with thalassemia major using shear wave elastography. <i>Hematology</i> , 2019, 24, 183-188.	0.7	16
78	Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2021, 56, 1190-1199.	1.3	16
79	Clinical course and outcomes of COVID-19 in hematopoietic cell transplant patients, a regional report from the Middle East. <i>Bone Marrow Transplantation</i> , 2021, 56, 2144-2151.	1.3	16
80	Perinatal Outcome of Monochorionic in Comparison to Dichorionic Twin Pregnancies. <i>Oman Medical Journal</i> , 2013, 28, 173-177.	0.3	16
81	Transfusion indication predictive score: a proposed risk stratification score for perioperative red blood cell transfusion in cardiac surgery. <i>Vox Sanguinis</i> , 2014, 107, 269-275.	0.7	15
82	High-resolution HLA phased haplotype frequencies to predict the success of unrelated donor searches and clinical outcome following hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1701-1709.	1.3	15
83	Predictors of impaired bone health in long-term survivors after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1651-1661.	1.3	15
84	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	0.6	15
85	Adult Precursor T-Lymphoblastic Leukemia/Lymphoma with Myeloid-Associated Antigen Expression Is Associated with a Lower Complete Remission Rate following Induction Chemotherapy. <i>Acta Haematologica</i> , 2008, 120, 5-10.	0.7	14
86	T2* MRI in Regularly Transfused Children with Thalassemia Intermedia: Serum Ferritin Does Not Reflect Liver Iron Stores. <i>Pediatric Hematology and Oncology</i> , 2012, 29, 579-584.	0.3	14
87	The pneumatic tube system does not affect complete blood count results; a validation study at a tertiary care hospital. <i>International Journal of Laboratory Hematology</i> , 2014, 36, 514-520.	0.7	14
88	Successful management of severe hemolytic disease of the fetus due to anti-K <sub>1b</sub> using intrauterine transfusions with serial maternal blood donations: a case report and a review of the literature. <i>Transfusion</i> , 2014, 54, 238-243.	0.8	14
89	Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation. <i>Cytotherapy</i> , 2018, 20, 453-460.	0.3	14
90	Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2020, 55, 1763-1772.	1.3	14



#	ARTICLE	IF	CITATIONS
91	Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 884-890.	1.3	13
92	Tear Proteomic Predictive Biomarker Model for Ocular Graft Versus Host Disease Classification. <i>Translational Vision Science and Technology</i> , 2020, 9, 3.	1.1	13
93	Intraoperative cell salvage in cardiac surgery may increase platelet transfusion requirements: a cohort study. <i>Vox Sanguinis</i> , 2015, 109, 280-286.	0.7	12
94	Discriminatory power of the intraoperative cell salvage use in the prediction of platelet and plasma transfusion in patients undergoing cardiac surgery. <i>Transfusion and Apheresis Science</i> , 2015, 53, 208-212.	0.5	12
95	Safety of stem cell mobilization in donors with sickle cell trait. <i>Bone Marrow Transplantation</i> , 2015, 50, 310-311.	1.3	12
96	The survey on cellular and tissue-engineered therapies in Europe and neighboring Eurasian countries in 2014 and 2015. <i>Cytotherapy</i> , 2018, 20, 1-20.	0.3	12
97	Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis. <i>Haematologica</i> , 2019, 104, 1230-1236.	1.7	12
98	Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation – A Single Centre Study. <i>Anticancer Research</i> , 2020, 40, 5909-5917.	0.5	12
99	Guideline-based indicators for adult patients with myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 4029-4044.	2.5	12
100	Immunological predictors of disease severity in patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 110, 83-92.	1.5	12
101	Prevalence of Red Blood Cell Major Blood Group Antigens and Phenotypes among Omani Blood Donors. <i>Oman Medical Journal</i> , 2019, 34, 496-503.	0.3	12
102	Validation of a Non-Invasive Hemoglobin Estimation in Whole Blood Donors. <i>Blood</i> , 2012, 120, 2280-2280.	0.6	12
103	Negative Impact Of KIR/HLA Interactions On NK Cell Activity Can Be Overcome By The Glycoengineered Antibody GA101 (Obinutuzumab). <i>Blood</i> , 2013, 122, 376-376.	0.6	12
104	20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2022, 28, 1004-1012.	3.2	12
105	Methemoglobinemia in an Elderly Patient with Glucose-6-Phosphate Dehydrogenase Deficiency: A Case Report. <i>Oman Medical Journal</i> , 2014, 29, 135-137.	0.3	11
106	Intra-arterial catheter guided steroid administration for the treatment of steroid-refractory intestinal GvHD. <i>Leukemia Research</i> , 2014, 38, 184-187.	0.4	11
107	The Survey on Cellular and Engineered Tissue Therapies in Europe in 2013. <i>Tissue Engineering - Part A</i> , 2016, 22, 5-16.	1.6	11
108	Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia – A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2017, 92, 18-22.	2.0	11

#	ARTICLE	IF	CITATIONS
109	Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study. <i>Transplant Infectious Disease</i> , 2020, 22, e13289.	0.7	11
110	Correlation of Iron Overload and Glomerular Filtration Rate Estimated by Cystatin C in Patients with $\beta^2$ -Thalassemia Major. <i>Hemoglobin</i> , 2014, 38, 365-368.	0.4	10
111	Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 507-513.	2.0	10
112	Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. <i>American Journal of Hematology</i> , 2018, 93, 1532-1542.	2.0	10
113	Common oral diseases, hyposalivation and survival post-HSCT, a longitudinal study. <i>European Journal of Haematology</i> , 2019, 103, 300-306.	1.1	10
114	Knowledge and Attitudes Towards Clinical Trial Participation in Oman: A cross-sectional study. <i>Sultan Qaboos University Medical Journal</i> , 2018, 18, 54.	0.3	10
115	Outcome of Late-onset Neonatal Sepsis at a Tertiary Hospital in Oman. <i>Oman Medical Journal</i> , 2019, 34, 302-307.	0.3	10
116	Maternal Complications and The Association with Baseline Variables in Pregnant Women with Sickle Cell Disease. <i>Hemoglobin</i> , 2013, 37, 219-226.	0.4	9
117	Knowledge and Attitudes of Oman Medical Specialty Board Residents towards Evidence-Based Medicine. <i>Oman Medical Journal</i> , 2014, 29, 178-184.	0.3	9
118	Evaluation of the Pretransplantation Workup before Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1852-1856.	2.0	9
119	Temperature-Sensitive Indicators for Monitoring RBC Concentrates Out of Controlled Temperature Storage. <i>American Journal of Clinical Pathology</i> , 2015, 144, 145-150.	0.4	9
120	Haploidentical hematopoietic bone marrow transplantation followed by living kidney transplantation from the same donor in a sickle cell disease patient with end-stage renal failure. <i>Annals of Hematology</i> , 2017, 96, 703-705.	0.8	9
121	Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party. <i>Haematologica</i> , 2017, 102, e271-e274.	1.7	9
122	Allogeneic stem cell transplantation for acquired pure red cell aplasia. <i>American Journal of Hematology</i> , 2019, 94, E294-E296.	2.0	9
123	Common oral diseases in allogeneic haematopoietic stem cell transplantation (HSCT) recipients pre-HSCT. <i>European Journal of Haematology</i> , 2019, 102, 351-356.	1.1	9
124	Histologic features of hematopoietic stem cell transplant-associated thrombotic microangiopathy are best perceived in deep skin biopsies and renal biopsies, while showing a significant overlap with changes related to severe acute graft-versus-host disease in gastrointestinal biopsies. <i>Bone Marrow Transplantation</i> , 2020, 55, 1847-1850.	1.3	9
125	Applications and challenges in therapeutic drug monitoring of cancer treatment: A review. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 693-701.	0.5	9
126	The Revised IPSS (IPSS-R) At Transplant Predicts Overall and Relapse-Free Survival After Allogeneic Stem Cell Transplantation In MDS/sAML: A Retrospective Analysis Of The EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2013, 122, 922-922.	0.6	9



#	ARTICLE	IF	CITATIONS
127	Perinatal Outcome in Pregnancies with Extreme Preterm Premature Rupture of Membranes ( ) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.3	8
128	Increase of endothelial progenitor cells in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. <i>Leukemia Research</i> , 2016, 47, 22-25.	0.4	8
129	Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2016, 95, 1627-1636.	0.8	8
130	Biological markers of hemostasis and endothelial activation in patients with a hematological malignancy with or without stem cell transplants. <i>European Journal of Haematology</i> , 2019, 103, 472-477.	1.1	8
131	Impact of cell saver during cardiac surgery on blood transfusion requirements: a systematic review and meta-analysis. <i>Vox Sanguinis</i> , 2019, 114, 553-565.	0.7	8
132	Dissociations of oral foci of infections with infectious complications and survival after haematopoietic stem cell transplantation. <i>PLoS ONE</i> , 2019, 14, e0225099.	1.1	8
133	Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH). <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 249.	1.2	8
134	Cardiac T2* MR in patients with thalassemia major: a 10-year long-term follow-up. <i>Annals of Hematology</i> , 2020, 99, 2009-2017.	0.8	8
135	Characteristics and Outcomes of Patients with Cerebral Venous Sinus Thrombosis. <i>Oman Medical Journal</i> , 2019, 34, 434-437.	0.3	8
136	Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients. <i>Medical Mycology</i> , 2021, 59, 701-711.	0.3	8
137	Angiogenic markers in plasma cell myeloma patients treated with novel agents. <i>Anticancer Research</i> , 2015, 35, 1085-90.	0.5	8
138	Hematopoietic stem cell transplantation in the Sultanate of Oman. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 305-307.	0.6	7
139	Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation. <i>British Journal of Haematology</i> , 2019, 184, 294-298.	1.2	7
140	Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP. <i>European Journal of Haematology</i> , 2020, 104, 181-189.	1.1	7
141	Optimal Treatment Duration of <i>Pseudomonas aeruginosa</i> Infections in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa246.	0.4	7
142	Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 210-217.	1.3	7
143	Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1944-1952.	1.3	7
144	Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBMT) group and severe aplastic anemia working party of the European Society for blood and marrow transplantation (SAAWP of EBMT). <i>Bone Marrow Transplantation</i> , 2021, 56, 2518-2532.	1.3	7

#	ARTICLE	IF	CITATIONS
145	Prevalence and persistence of SARS-CoV2 antibodies among healthcare workers in Oman. <i>Journal of Infection and Public Health</i> , 2021, 14, 1578-1584.	1.9	7
146	Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis; A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01). <i>Blood</i> , 2019, 134, 614-614.	0.6	7
147	Pulmonary valve regurgitation following balloon valvuloplasty for pulmonary valve stenosis: Single center experience. <i>Annals of Pediatric Cardiology</i> , 2013, 6, 141.	0.2	6
148	Validation of a noninvasive pulse oximetry-based hemoglobin estimation in patients with sickle cell disease. <i>International Journal of Laboratory Hematology</i> , 2013, 35, e21-3.	0.7	6
149	Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. <i>Bone Marrow Transplantation</i> , 2019, 54, 2060-2071.	1.3	6
150	Echocardiographic Evidence of Early Diastolic Dysfunction in Asymptomatic Children with Osteogenesis Imperfecta. <i>Sultan Qaboos University Medical Journal</i> , 2015, 15, e456-e462.	0.3	6
151	Genital Ulcer Development in Patients with Acute Promyelocytic Leukaemia Treated with All-Trans Retinoic Acid: A Case Series. <i>Oman Medical Journal</i> , 2013, 28, 207-209.	0.3	6
152	HEV infection in stem cell transplant recipients: retrospective study of EBMT Infectious Diseases Working Party. <i>Bone Marrow Transplantation</i> , 2022, 57, 167-175.	1.3	6
153	Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. <i>Annals of Hematology</i> , 2021, 100, 1169-1179.	0.8	5
154	Upfront Alternative Donor Transplant versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack a Fully HLA-Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies, on Behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 105.e1-105.e7.	0.6	5
155	Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 224-231.	1.3	5
156	Rituximab Leads to Long Remissions in Patients with Chronic Immune Thrombocytopenia. <i>Oman Medical Journal</i> , 2015, 30, 111-114.	0.3	4
157	Stability of fetal hemoglobin levels in patients receiving metformin therapy. <i>Haematologica</i> , 2018, 103, e440-e442.	1.7	4
158	Transfusion knowledge of medical and surgical specialty board residents: a cohort study. <i>Transfusion Medicine</i> , 2018, 28, 440-450.	0.5	4
159	Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2020, 112, 210-216.	0.7	4
160	Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020, 190, 437-441.	1.2	4
161	Does the order of mutational acquisition in myeloproliferative neoplasms matter? Evidence from JAK2 exon 12 and DNMT3A co-mutant polycythemia vera. <i>Journal of Hematopathology</i> , 2020, 13, 105-107.	0.2	4
162	Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 23-30.	1.3	4

#	ARTICLE	IF	CITATIONS
163	Effects of the Sympathomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2-Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14. <i>Blood</i> , 2016, 128, 3108-3108.	0.6	4
164	Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantationâ€“study on behalf of CMWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 633-640.	1.3	4
165	Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1072-1078.	1.3	4
166	Human macrophages and monocyte-derived dendritic cells stimulate the proliferation of endothelial cells through midkine production. <i>PLoS ONE</i> , 2022, 17, e0267662.	1.1	4
167	Obstacles to Widening Biosample Research. <i>Science and Engineering Ethics</i> , 2019, 25, 113-128.	1.7	3
168	The Survey on Cellular and Tissue-Engineered Therapies in Europe in 2016 and 2017. <i>Tissue Engineering - Part A</i> , 2021, 27, 336-350.	1.6	3
169	Current practice of oral care for hematopoietic stem cell transplant patients: A survey of the Eastern Mediterranean Blood and Marrow transplantation group. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	3
170	Conditioning intensity before allogeneic haematopoietic stem cell transplantation: a quality control audit. <i>British Journal of Haematology</i> , 2021, 192, e151-e154.	1.2	3
171	Correlation of expression of Akt1 and E2F1 and their phosphorylated forms in breast cancer patients with clinicopathological parameters. <i>Journal of Molecular Histology</i> , 2021, 52, 621-633.	1.0	3
172	Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey. <i>Bone Marrow Transplantation</i> , 2020, 55, 2335-2338.	1.3	3
173	A Rare Case of Congenital Atransferrinemia: International Collaboration for Genetic Diagnosis. <i>Blood</i> , 2014, 124, 4883-4883.	0.6	3
174	Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation. <i>Swiss Medical Weekly</i> , 2019, 149, w20150.	0.8	3
175	Transfusion Consent in Oman: Physiciansâ€™ Perception at a Tertiary Care University Hospital. <i>Oman Medical Journal</i> , 2016, 31, 253-257.	0.3	3
176	Late Mortality Following Allogeneic Stem Cell Transplantation Is Closely Associated with Chronic Graft Versus Host Disease but Not with Donor Type.. <i>Blood</i> , 2004, 104, 56-56.	0.6	3
177	The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed. <i>Cancer Medicine</i> , 2022, 11, 630-640.	1.3	3
178	Dkk3 levels in patients with myeloproliferative neoplasms. <i>Thrombosis Research</i> , 2014, 133, 218-221.	0.8	2
179	Stem Cell Transplantation in Patients with Sickle Cell Disease. , 2016, , .		2
180	Fungemia and necrotic lymph node infection with <i>Sporopachydermia cereana</i> in a patient with acute myeloid leukemia. <i>International Journal of Infectious Diseases</i> , 2017, 61, 103-106.	1.5	2

#	ARTICLE	IF	CITATIONS
181	Recombinant factorÂIII Aâsubunit in a patient with factorÂIII deficiency and recurrent pregnancy loss. Journal of Thrombosis and Haemostasis, 2018, 16, 1052-1054.	1.9	2
182	Successful Management of Endometriosis, <i>In Vitro</i> Fertilization, Pregnancy, and Postpartum Recovery in a Woman with Glanzmann's Thrombasthenia. Journal of Gynecologic Surgery, 2019, 35, 321-323.	0.0	2
183	Measurement of hematopoietic progenitor cells using XN2000 hematology analyzer. International Journal of Laboratory Hematology, 2022, 44, 82-87.	0.7	2
184	Abandoning Care in Laminar Air Flow (LAF) Units and Routine High Dose Intravenous Immunoglobulines (IVIg) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Does Not Increase Mortality and Rate of Infections.. Blood, 2004, 104, 5072-5072.	0.6	2
185	Liver Enzymes Changes and Safety Profile of Deferasirox Iron Chelator in Omani Children with Thalassemia Major. Blood, 2014, 124, 4903-4903.	0.6	2
186	Impact of Home-to-Centre Distance on Bone Marrow Transplantation Outcomes. Sultan Qaboos University Medical Journal, 2019, 19, 15.	0.3	2
187	Reproducibility of Manual Platelet Estimation Following Automated Low Platelet Counts. Oman Medical Journal, 2016, 31, 409-413.	0.3	2
188	Immunophenotypic Characteristics of T-Acute Lymphoblastic Leukemia in Omani Patients: A Correlation with Demographic Factors. Oman Medical Journal, 2018, 33, 43-47.	0.3	2
189	Impact of Blood Transfusion on Troponin I Levels and Outcomes after Cardiac Surgery: A Cohort Study. Oman Medical Journal, 2019, 34, 14-19.	0.3	2
190	Overall Survival in Patients with JAK2 and ASXL1 Positive Myeloproliferative Neoplasms. Blood, 2019, 134, 5383-5383.	0.6	2
191	Allogeneic, CD34 +, Umbilical Cordblood-Derived NK Cell Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease. Blood, 2021, 138, 1745-1745.	0.6	2
192	Impact of Glutathione S-Transferase Polymorphisms on Busulfan Pharmacokinetics and Outcomes of Hematopoietic Stem Cell Transplantation. Therapeutic Drug Monitoring, 2022, 44, 527-534.	1.0	2
193	Fetal outcomes in pregnant women with sickle cell disease. Journal of King Abdulaziz University, Islamic Economics, 2014, 35, 472-6.	0.5	2
194	Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. Bone Marrow Transplantation, 2022, 57, 896-902.	1.3	2
195	Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia with Busulfan-Based Reduced Intensity Conditioning: Cure and Fertility. Biology of Blood and Marrow Transplantation, 2013, 19, S285-S286.	2.0	1
196	Concomitant microfilaria and malaria infection. Blood, 2013, 121, 4437-4437.	0.6	1
197	Response to Dr. Rice M and colleagues on their Letter to Editor regarding âValidation of a non-invasive pulse CO-oximetry based hemoglobin estimation in normal blood donors,âTransfusion and Apheresis Science 2013 Nov 4. Accurate Enough for the Spectrum Tested. Transfusion and Apheresis Science, 2014, 51, 84-85.	0.5	1
198	Combined Factor V and VIII Deficiency. Oman Medical Journal, 2018, 33, 268-268.	0.3	1

#	ARTICLE	IF	CITATIONS
199	Patient preferences for allogeneic haematopoietic stem cell transplantation: how much benefit is worthwhile from the patient's perspective?. Supportive Care in Cancer, 2021, 29, 3129-3135.	1.0	1
200	Legionellosis after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 2555-2566.	1.3	1
201	Possible Reactivation of SARS-CoV-2 in a Patient with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Case Report. SN Comprehensive Clinical Medicine, 2021, 3, 2011-2015.	0.3	1
202	Influence of HLA-DPB1 mismatches on outcome after allogeneic hematopoietic stem cell transplantation. Leukemia Research Reports, 2021, 16, 100259.	0.2	1
203	The Optimal Cut-Off Level for Hemoglobin A2 to Differentiate between Sickle Cell Disease Genotypes. Blood, 2018, 132, 2391-2391.	0.6	1
204	Long Term Follow up of Patients with Immune Thrombocytopenia Receiving Rituximab. Blood, 2011, 118, 4675-4675.	0.6	1
205	Long-Term Iron Chelation Therapy with Deferiprone in Patients with Thalassemia Major and Low Iron Load. Blood, 2016, 128, 3626-3626.	0.6	1
206	Reactive Hemophagocytic Syndrome after Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). Blood, 2016, 128, 4617-4617.	0.6	1
207	First Implementation of Transfusion Consent Policy in Oman: Audit of compliance from a tertiary care university hospital. Sultan Qaboos University Medical Journal, 2016, 16, e293-297.	0.3	1
208	Molecular blood group screening in Omani blood donors. Vox Sanguinis, 2022, 117, 424-430.	0.7	1
209	High Dose Chemotherapy and Autologous Stem Cell Transplantation in the Primary Therapy of Advanced Follicular Lymphoma in Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.. Blood, 2009, 114, 2314-2314.	0.6	1
210	Validation of a Non-Invasive Hemoglobin Estimation in Patients with Sickle Cell Disease. Blood, 2012, 120, 4770-4770.	0.6	1
211	Evaluation Of The Pre-Transplantation Workup Before Allogeneic Transplantation and Reasons For Delaying Or Cancelling Transplant. Blood, 2013, 122, 5456-5456.	0.6	1
212	Travelling activity and travel-related risks after allogeneic haematopoietic stem cell transplantation – a single centre survey. Swiss Medical Weekly, 2015, 145, w14136.	0.8	1
213	Sickle Cell Disease Patients with Systemic Lupus Erythematosus Exhibit Quantitative and Qualitative Impairments in Circulating B Regulatory Cells. Blood, 2016, 128, 3641-3641.	0.6	1
214	Family Mismatched Donor Transplantation for Myelofibrosis: A Retrospective Analysis of the EBMT Chronic Leukaemia Working Party. Blood, 2016, 128, 4655-4655.	0.6	1
215	Understanding Iron Metabolism: Lessons from Transfusion-dependent Thalassemia. Oman Medical Journal, 2018, 33, 1-2.	0.3	1
216	Pseudopyropoikilocytosis leading to spurious results. Sultan Qaboos University Medical Journal, 2014, 14, e259-60.	0.3	1

#	ARTICLE	IF	CITATIONS
217	Recognition, Investigation and Management of Acute Transfusion Reactions: Consensus guidelines for Oman. Sultan Qaboos University Medical Journal, 2014, 14, e306-18.	0.3	1
218	Patientsâ€™ knowledge and awareness of safe handling of oral anticancer agents at Sultan Qaboos University Hospital in Oman. Journal of Oncology Pharmacy Practice, 2023, 29, 112-118.	0.5	1
219	Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in Europe between 1995-2018: An EBMT Retrospective Analysis. Blood, 2020, 136, 38-39.	0.6	1
220	Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT. Bone Marrow Transplantation, 2022, , .	1.3	1
221	Gene-expression Profiling in Patients with Plasma Cell Myeloma Treated with Novel Agents. Cancer Genomics and Proteomics, 2016, 13, 275-9.	1.0	1
222	Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia. Hematological Oncology, 2022, 40, 1100-1104.	0.8	1
223	Long Term Outcomes of Allogeneic Transplant Using Non-Radiation Based Preparative Regimens for Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2011, 17, S313.	2.0	0
224	A Single Daily Ultra Low-Dose of Oral Acyclovir Is Sufficient to Prevent the Occurrence of Herpes Zoster Post Hematopoietic Stem Cell Transplantation: Interim Results of a Prospective Randomized Trial. Biology of Blood and Marrow Transplantation, 2013, 19, S261-S262.	2.0	0
225	Safety of Stem Cell Mobilization in Donors with Sickle Cell Trait. Biology of Blood and Marrow Transplantation, 2014, 20, S214.	2.0	0
226	Graft Versus Leukemia Effect Is Overestimated in Studies with High Rates of Graft Versus Host Disease Related Mortality: A Simulation Study. Biology of Blood and Marrow Transplantation, 2015, 21, S322-S323.	2.0	0
227	Patients with Lower Clearance of Busulfan Have Higher Risk of Graft Loss When Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, S301.	2.0	0
228	What the internist should know about stem cell transplant in the elderly patient. European Journal of Internal Medicine, 2018, 58, 43-47.	1.0	0
229	Severe anemia after trans-catheter arterial chemoembolizationâ€”an unusual presentation of hemoglobin Zurich. Annals of Hematology, 2018, 97, 2249-2251.	0.8	0
230	Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis. Lancet Haematology, 2020, 7, e364.	2.2	0
231	Unique aspects of Graft-versus-host-disease management in the Eastern Mediterranean region: Report from the Eastern Mediterranean blood and marrow transplantation group: Special report. Hematology/ Oncology and Stem Cell Therapy, 2020, , .	0.6	0
232	Efficiency of day 4 compared to day 6 stem cell mobilization in allogeneic stem cell donors. Transfusion and Apheresis Science, 2020, 59, 102727.	0.5	0
233	Antenatal predictors of stem cell content for successful umbilical cord blood donation. Archives of Gynecology and Obstetrics, 2021, 304, 377-384.	0.8	0
234	An ounce of which prevention is worth aâ€¦?. Blood, 2021, 137, 1852-1853.	0.6	0



#	ARTICLE	IF	CITATIONS
235	A prospective phase I/IIa trial to evaluate the safety and efficacy of GTA002, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation in patients with acute myeloid leukemia in complete morphological remission who have measurable residual disease.. Journal of Clinical Oncology, 2021, 39, TPS7053-TPS7053.	0.8	0
236	Balancing risk in a patient with primary bone histiocytic sarcoma during pregnancy: Case report and review of the literature. International Journal of Surgery Case Reports, 2021, 83, 106021.	0.2	0
237	Incidence and impact of Epstein-Barr virus events in the early phase after allogeneic hematopoietic cell transplantation. Annals of Hematology, 2021, 100, 1913-1915.	0.8	0
238	Myeloid-Associated Antigen Expression Is an Adverse Factor for Complete Remission Following Induction Chemotherapy of Adult Precursor T-Lymphoblastic Leukemia/Lymphoma (T-ALL).. Blood, 2007, 110, 4228-4228.	0.6	0
239	Treatment of Adult T-ALL with a Pediatric Asparaginase-Intensive Protocol Results in Survival Benefit When Compared to Other Adult Based Protocols. Blood, 2008, 112, 3956-3956.	0.6	0
240	Impact of the Intensity of Conditioning Therapy On the Outcomes of Patients Aged 40 to 60 Years with Acute Myeloid Leukemia/Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation.. Blood, 2009, 114, 1202-1202.	0.6	0
241	Prevalence of Thrombophilia In Patients with Sickle Cell Disease and Osteonecrosis. Blood, 2010, 116, 3184-3184.	0.6	0
242	Validation of Monosomal Karyotype Based Model In the Risk Stratification of Acute Myeloid Leukemia. Blood, 2010, 116, 2745-2745.	0.6	0
243	Inherited Thrombophilia In Omani Women with Recurrent Pregnancy Loss. Blood, 2010, 116, 5124-5124.	0.6	0
244	A Prognostic Score of Overall Survival In Adults with Acute Myeloid Leukemia. Blood, 2010, 116, 2730-2730.	0.6	0
245	Dose Optimization of Deferasirox in Chelation Naïve Children with Thalassemia Major. Blood, 2011, 118, 5294-5294.	0.6	0
246	T2* MRI in Hypertransfused Children with Thalassemia Intermedia: Serum Ferritin Does Not Reflect the Reality. Blood, 2011, 118, 5304-5304.	0.6	0
247	Gonadal Function In Patients with Beta-Thalassemia Major Following Bone Marrow Transplantation,. Blood, 2011, 118, 4105-4105.	0.6	0
248	Non-Invasive Hemoglobin Estimation in Patients with $\beta^2$ -Thalassemia Major. Blood, 2012, 120, 5179-5179.	0.6	0
249	Heparin Does Not Increase Live Births in Pregnant Women with Previous Unexplained Recurrent Miscarriages: A Systematic Review and Meta-Analysis. Blood, 2012, 120, 504-504.	0.6	0
250	Intra-Arterial Catheter Guided Steroid Administration For The Treatment Of Steroid-Refractory Intestinal GvHD. Blood, 2013, 122, 4604-4604.	0.6	0
251	Pulmonary Hypertension in Sickle Cell Disease: Correlation With Echocardiographic Assessment and Serum Brain Natriuretic Peptide Concentration. Blood, 2013, 122, 4680-4680.	0.6	0
252	Outcome Of Aplastic Anemia In Adolescence. A Survey Of The Severe Aplastic Anemia Working Party (SAAWP) Of The European Blood and Bone Marrow Transplant Group (EBMT). Blood, 2013, 122, 2481-2481.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Similar Outcome of Upfront Unrelated and Matched Sibling Donor Hematopoietic Stem Cell Transplantation in Idiopathic Aplastic Anaemia of Childhood and Adolescence: A Cohort Controlled Study on Behalf of the UK Paediatric BMT WP, of the PD WP and of the SAA WP of the EBMT. <i>Blood</i> , 2014, 124, 256-256.	0.6	0
254	Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome (MDS) Patients at Lower Risk According to International Prognostic Scoring System (IPSS) : A Retrospective Study on Behalf of the CmwP of the EBMT. <i>Blood</i> , 2014, 124, 2530-2530.	0.6	0
255	Influence of Preexisting Invasive Aspergillosis on Allo-HSCT Outcome: A Retrospective EBMT Analysis from the Infectious Diseases and Acute Leukemia Working Parties. <i>Blood</i> , 2014, 124, 185-185.	0.6	0
256	Outcomes after Double Umbilical Cord Blood Transplantation in Children: A Survey on Behalf of Eurocord and PDWP-EBMT. <i>Blood</i> , 2014, 124, 2570-2570.	0.6	0
257	Allogeneic Hematopoietic Stem Cells Transplantation for Non-Hodgkinâ€™s Lymphoma. The Swiss Experience 1985-2014. <i>Blood</i> , 2014, 124, 1256-1256.	0.6	0
258	Delivering a Hemophilic Newborn with No Intracranial Hemorrhage: Is Caesarian Section the Answer?. <i>Blood</i> , 2014, 124, 5060-5060.	0.6	0
259	Circulating Invariant Natural Killer T Cell Subsets Are Functionally Preserved in Splenectomized Children with Sickle Cell Disease Compared to Patients with Large Spleen. <i>Blood</i> , 2015, 126, 3389-3389.	0.6	0
260	Unusual Indolent Course of a Chronic Active Epstein-Barr Virus-Associated Natural Killer Cell Lymphoproliferative Disorder. <i>Sultan Qaboos University Medical Journal</i> , 2016, 16, e230-233.	0.3	0
261	Influence of Genetic Modifiers on Levels of Invariant Natural Killer T-Cells in Patients with Sickle Cell Anemia. <i>Blood</i> , 2016, 128, 4843-4843.	0.6	0
262	Analysis of the Early Clonal Dynamics in Ibrutinib-Treated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4367-4367.	0.6	0
263	Genotype in Patients with Thalassemia Major Has No Impact on Risk of Liver Fibrosis. <i>Blood</i> , 2016, 128, 4835-4835.	0.6	0
264	An Alternative Donor Is a Valid Option Compared to a Matched-Unrelated in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in CR2: A Report of 841 Patients from the EBMT Acute Leukemia Working Party. <i>Blood</i> , 2016, 128, 3497-3497.	0.6	0
265	Male Gender Increases the Risk of Liver Fibrosis in Patients with Thalassemia Major Independent of Iron Overload. <i>Blood</i> , 2016, 128, 3630-3630.	0.6	0
266	Impact of Aberrant Myeloid Antigen Expression on Outcomes of Patients with T-cell Acute Lymphoblastic Leukemia. <i>Oman Medical Journal</i> , 2017, 32, 189-193.	0.3	0
267	Second-line therapy to improve overall survival in primary refractory non small-cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21069-e21069.	0.8	0
268	Feasibility of HSCT vs consolidation therapy for AML patients aged 60-75 in CR1: A randomized phase III, multicentre EBMT study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7045-7045.	0.8	0
269	The Demographic, Clinical and Survival Rate of Classical Hogkings Lymphoma Patients in Oman, Retrospective Study. <i>Blood</i> , 2018, 132, 5369-5369.	0.6	0
270	Incorporation of Clinical Information to Decipher Driver Mutations in Myeloproliferative Neoplasms. <i>Blood</i> , 2018, 132, 5489-5489.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Incorporation of Evidence Based Guidelines on Bleeding Risk Assessment PRIOR to Ent Surgery into Practice: Real Time Experience. Blood, 2018, 132, 4714-4714.	0.6	0
272	Impact of Human Leukocyte Antigen on the Risk of Stroke in Patients with Sickle Cell Disease. Blood, 2019, 134, 4831-4831.	0.6	0
273	Clinical and Magnetic Resonance Imaging (MRI) Decision Making Rules in Differentiating Vaso-Occlusive Crises (VOCs) from Osteomyelitis in Paediatric Sickle Cell Population: Is MRI Pathognomonic?. Blood, 2019, 134, 4824-4824.	0.6	0
274	Prevalence, Clinical Characteristics and Outcome of Von Willebrand Disease in Oman. Blood, 2019, 134, 4939-4939.	0.6	0
275	"Prevalence and Outcome of Avascular Necrosis of the Hip (AVN) Among Young Omani Patients with Sickle Cell Disease". Blood, 2019, 134, 3577-3577.	0.6	0
276	Impact of Mutations in Epigenetic Modifiers in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Blood, 2019, 134, 2604-2604.	0.6	0
277	Two-Year Landmark Survival Analysis after Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia: An Analysis from the ALWP of the EBMT. Blood, 2021, 138, 1822-1822.	0.6	0
278	Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT. Blood, 2020, 136, 26-27.	0.6	0
279	Does a Change in IPSS-R between Diagnosis and Transplant Have an Impact on Transplant Outcome in Patients with MDS? a Retrospective Analysis from the EBMT Chronic Malignancies Working Party. Blood, 2020, 136, 39-40.	0.6	0
280	Upfront Alternative Donor Transplant Versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack Fully HLA Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies. on Behalf of the Severe Aplastic Anemia Working Party of European Group for Blood and Marrow Transplantation (SAAWP of EBMT). Blood, 2020, 136, 6-7.	0.6	0
281	Reply from the author. Journal of King Abdulaziz University, Islamic Economics, 2014, 35, 1160.	0.5	0